author-photo

Krischan J Hudson

Research Triangle Park

16

Papers

470

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

2021 The Lancet HIV
Show All
- Source
- Cite
- Save
Citations (0)
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

2020 Journal of Acquired Immune Deficiency Syndromes
Show All
- Source
- Cite
- Save
Citations (16)
Feasibility of implementing long-acting injectable anti-retroviral therapy to treat HIV: a survey of health providers from the 13 countries participating in the ATLAS-2M trial

2020 AIDS Research and Human Retroviruses
Show All
- Source
- Cite
- Save
Citations (1)
LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

2020 Open Forum Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (1)
Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial.

2020
Show All
- Source
- Cite
- Save
Citations (3)
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

2020 The Lancet
Show All
- Source
- Cite
- Save
Citations (32)
2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies

2019 Open Forum Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (3)
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

2018 Hiv Clinical Trials
Show All
- Source
- Cite
- Save
Citations (31)
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

2017 The Lancet HIV
Show All
- Source
- Cite
- Save
Citations (134)
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

2015 Lancet Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (131)